Company Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases.
It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.
In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer.
It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited.
The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013.
Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2013 |
| IPO Date | Feb 3, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 265 |
| CEO | Dr. Gilmore O'Neill M.D. |
Contact Details
Address: 11 Hurley St. Cambridge, Massachusetts 02141 United States | |
| Phone | 617-401-9000 |
| Website | editasmedicine.com |
Stock Details
| Ticker Symbol | EDIT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001650664 |
| CUSIP Number | 28106W103 |
| ISIN Number | US28106W1036 |
| Employer ID | 46-4097528 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Gilmore O'Neill M.D. | President, Chief Executive Officer and Director |
| Dr. Baisong Mei M.D., Ph.D. | Senior Vice President and Chief Medical Officer |
| Dr. Feng Zhang Ph.D. | Co-Founder and Scientific Advisory Board Member |
| Dr. George McDonald Church Ph.D. | Co-Founder and Scientific Advisory Board Member |
| Dr. J. Keith Joung M.D., Ph.D. | Co-Founder and Scientific Advisory Board Member |
| Dr. David R. Liu Ph.D. | Co-Founder and Scientific Advisory Board Member |
| Erick J. Lucera C.F.A., CPA | Chief Financial Officer and Executive Vice President |
| Dr. Linda C. Burkly Ph.D. | Executive Vice President and Chief Scientific Officer |
| Cristi Barnett | Corporate Communications and Investor Relations |
| Charlene Stern J.D., Ph.D. | Executive Vice President and General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 16, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 10, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Mar 4, 2024 | 144 | Filing |
| Feb 28, 2024 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Feb 28, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 28, 2024 | 10-K | Annual Report |
| Feb 28, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |